Skye Bioscience, Inc.
For the period ended Mar 31, 2026. Filed May 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 11, 2026
SKYE$0.84+21.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows for the
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| For the Three Months EndedMarch 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net Loss | $(12,509,361) | $(11,103,319) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 172,886 | 177,379 |
| Stock-based compensation expense | 1,496,989 | 2,201,909 |
| Loss from disposal of assets | 7,615 | — |
| Changes in assets and liabilities: | ||
| Prepaid expenses | (396,781) | (373,420) |
| Right-of-use assets | 170,367 | — |
| Other current assets | 617,231 | (1,018,906) |
| Other assets | 18,001 | — |
| Accounts payable | 1,903,517 | 1,215,779 |
| Accrued payroll liabilities | (1,035,082) | (458,124) |
| Operating lease liability | (212,666) | (43,479) |
| Other current liabilities | 1,209,367 | 216,701 |
| Net cash used in operating activities | (8,557,917) | (9,185,480) |
| Cash flows from investing activities: | ||
| Maturities/(purchase) of short-term investments, net of maturities | 10,895,109 | (12,802,650) |
| Purchase of property and equipment | — | (6,312) |
| Cash from asset disposition | 850 | — |
| Net cash provided by (used in) investing activities | 10,895,959 | (12,808,962) |
| Cash flows from financing activities: | ||
| Repayment of insurance premium loan payable | (71,525) | — |
| Net cash used in financing activities | (71,525) | — |
| Net increase (decrease) in cash and cash equivalents | 2,266,517 | (21,994,442) |
| Cash and cash equivalents, beginning of period | $5,882,498 | $68,415,741 |
| Cash and cash equivalents, end of period | $8,149,015 | $46,421,299 |
| Cash paid during the year for: | ||
| Interest | $2,199 | $— |
| Income taxes | — | 2,000 |
| Supplemental disclosures of non-cash financing activities: | ||
| Financing of D&O insurance premium | $321,863 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.